Pathogenesis and management of lipoprotein disorders

N Engl J Med. 1985 May 16;312(20):1300-10. doi: 10.1056/NEJM198505163122007.
No abstract available

Publication types

  • Review

MeSH terms

  • Abetalipoproteinemia / metabolism
  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cholestyramine Resin / therapeutic use
  • Chylomicrons / metabolism
  • Colestipol / therapeutic use
  • Dietary Fats / administration & dosage
  • Female
  • Gemfibrozil
  • Humans
  • Hyperlipoproteinemia Type I / therapy
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / therapy
  • Hyperlipoproteinemia Type III / diagnosis
  • Hyperlipoproteinemia Type III / therapy
  • Hyperlipoproteinemia Type IV / diagnosis
  • Hyperlipoproteinemia Type IV / therapy
  • Hyperlipoproteinemia Type V / therapy
  • Hyperlipoproteinemias / metabolism
  • Hyperlipoproteinemias / therapy*
  • Hypobetalipoproteinemias / metabolism
  • Hypolipoproteinemias / metabolism
  • Hypolipoproteinemias / therapy*
  • Infant
  • Infant, Newborn
  • Lipoproteins, HDL / metabolism
  • Lipoproteins, LDL / metabolism
  • Lipoproteins, VLDL / metabolism
  • Male
  • Middle Aged
  • Niacin / therapeutic use
  • Pentanoic Acids / therapeutic use
  • Probucol / therapeutic use
  • Tangier Disease / metabolism

Substances

  • Chylomicrons
  • Dietary Fats
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Pentanoic Acids
  • Cholestyramine Resin
  • Niacin
  • Colestipol
  • Probucol
  • Gemfibrozil